News
NLSPW
0.1500
-15.68%
-0.0279
NLS Pharmaceutics Regains Compliance With Nasdaq's Shareholders Equity Rule; Shares Rise
NLS Pharmaceutics Regains Compliance With Nasdaq's Shareholders Equity Rule; Shares Rise
MT Newswires · 01/25 11:37
NLS Pharmaceutics CEO Issues Letter To Shareholders
Benzinga · 12/22/2022 13:33
BRIEF-NLS Pharmaceutics Ltd Files Prospectus To The Resale, From Time To Time, By The Selling Shareholders Of Up To 11.9 Mln Common Shares - SEC Filing
Reuters · 12/06/2022 22:22
NLS Pharmaceutics Announces Launch Of Paid For Named Patient Program With Mazindol ER For Idiopathic Hypersomnia, A Serious Sleep Disorder With No Approved Treatment Options In Europe
Benzinga · 11/23/2022 13:34
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, ann...
ACCESSWIRE · 11/02/2022 14:40
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, ann...
ACCESSWIRE · 09/08/2022 12:00
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disor...
ACCESSWIRE · 07/28/2022 12:30
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
NLS Pharmaceutics Ltd.(NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder...
ACCESSWIRE · 07/21/2022 12:30
BRIEF-Nls Pharmaceutics AG Announces Positive Interim Top-Line Data For Quilience (Mazindol Er) In Patients With Narcolepsy
reuters.com · 03/16/2022 11:37
BRIEF-Nls Pharmaceutics AG - Announces Patent Issuance In The United States For Its Mazindol Extended-Release Formulation
reuters.com · 01/04/2022 13:16
BRIEF-Nls Pharmaceutics AG - Announces Final Results From A Preclinical Study For Nls-4 (Lauflumide)
reuters.com · 11/30/2021 13:45
BRIEF-NLS Pharmaceutics Announces Preclinical Data Demonstrating The Potential Of NLS-4 (Lauflumide) To Treat Chronic Fatigue Associated With Long-Covid
reuters.com · 10/14/2021 12:41
From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Begin Presenting
Click To Tune In Here: https://www.youtube.com/watch?v=KS30Mcu5ei8
Click To Tune In Here:  · 09/29/2021 13:52
BRIEF-NLS Pharmaceutics Announces $20 Mln Standby Equity Distribution Agreement
reuters.com · 09/28/2021 12:46
BRIEF-NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation For Treating Narcolepsy
reuters.com · 05/18/2021 12:24
BRIEF-NLS Pharmaceutics Announces Patent Issuance In Europe
reuters.com · 05/05/2021 12:42
BRIEF-NLS Pharmaceutics Announces Issuance of Canadian Patent Covering Formulation Mazindol CR
reuters.com · 03/29/2021 12:56
BRIEF-NLS Pharmaceutics Obtains License To Full Regulatory Data For Sanorex
reuters.com · 03/12/2021 13:06
More
Webull provides a variety of real-time NLSPW stock news. You can receive the latest news about Nls Pharmaceutic through multiple platforms. This information may help you make smarter investment decisions.
About NLSPW
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.